Clinical Trials | January 29, 2026
Bausch Health’s RED-C phase 3 trials fall short, company committed to liver disease research
The trials, which enrolled over 1,000 patients across 398 sites in 17 countries, showed that the drug was safe and well-tolerated—but ultimately failed to deliver the hoped-for clinical results
